Clinical Trial Detail

NCT ID NCT02760797
Title A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

malignant mesothelioma

triple-receptor negative breast cancer

pancreatic cancer

melanoma

stomach cancer

colorectal cancer

ovarian cancer

Therapies

Emactuzumab + Selicrelumab

Age Groups: adult

No variant requirements are available.